Yes. A pharmacist should review donepezil with bladder medicines because some bladder drugs block acetylcholine, the chemical system donepezil is intended to support.
This opposing effect may complicate cognition, daily function, urinary symptoms, and treatment decisions. The concern mainly involves bladder antimuscarinics, also called anticholinergic medicines. The FDA-approved ARICEPT label warns that cholinesterase inhibitors can interfere with anticholinergic medicines, so the combination deserves an individualized review rather than an automatic judgment.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Which bladder medicines raise the concern?
- Why is cognition and daily function part of the review?
- Could donepezil itself affect urinary symptoms?
- What should the pharmacist check?
- How strong is the evidence?
- Frequently Asked Questions
Which bladder medicines raise the concern?
The 2023 American Geriatrics Society Beers Criteria identify several strong anticholinergics used for urinary incontinence: These medicines reduce bladder muscle activity by blocking acetylcholine. Donepezil works through the cholinergic system, so the medicines can push in opposite pharmacologic directions. The ARICEPT labeling specifically identifies this type of interaction as a concern.
U.S. National Library of Medicine's ARICEPT label The list is not a verdict that every person will experience harm. It identifies medicines that should prompt a closer look at the reason for treatment, the duration of use, symptoms, and the person's overall anticholinergic exposure.
- Oxybutynin
- Solifenacin
- Tolterodine
- Trospium
- Darifenacin
Why is cognition and daily function part of the review?
Older adults with dementia or cognitive impairment may be more vulnerable to central-nervous-system effects from anticholinergic medicines. The 2023 Beers Criteria recommend avoiding these medicines in this population when possible and state that oxybutynin has the strongest evidence for adverse cognitive effects, while urging caution with all bladder antimuscarinics. 2023 AGS Beers Criteria Functional changes matter as much as memory complaints.
In a study of higher-functioning nursing-home residents taking a cholinesterase inhibitor, concurrent oxybutynin or tolterodine was associated with a 50% faster quarterly decline in activities-of-daily-living scores than cholinesterase-inhibitor treatment alone. Journal of the American Geriatrics Society study That finding shows why a pharmacist may ask about dressing, bathing, toileting, walking, and managing routines. It does not prove that every donepezil–bladder-antimuscarinic combination causes functional decline.
Could donepezil itself affect urinary symptoms?
Donepezil can complicate the assessment in another direction. Its labeling warns that cholinomimetics may cause bladder-outflow obstruction, although this was not observed in ARICEPT clinical trials. U.S. National Library of Medicine's ARICEPT label That warning means urinary symptoms should not automatically be blamed on an anticholinergic bladder medicine.
A review may need to consider whether symptoms reflect overactive bladder, possible obstruction, treatment effects, or more than one factor. Claims data also show that urinary treatment needs arise among people starting cholinesterase inhibitors. In a Medicare cohort of 524,975 adults aged 65 or older with dementia, 5.07% developed an overactive-bladder diagnosis or received antimuscarinic or mirabegron therapy within six months. Donepezil had a higher adjusted overactive-bladder risk than rivastigmine in that analysis. 2021 Journal of the American Geriatrics Society study.
What should the pharmacist check?
A useful review connects the prescription to the person's actual symptoms and goals. It should examine: The 2024 American Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction guideline directs clinicians to discuss dementia and cognitive-impairment risk with patients using bladder antimuscarinics.
It also says a beta-3 agonist is typically preferred before chronic antimuscarinic treatment, making medication review relevant when ongoing therapy is being considered. 2024 AUA/SUFU guideline A pharmacist can organize these questions for the prescriber and identify whether the current regimen still fits the person's symptoms, cognition, function, and retention risk. The pharmacist should not independently stop donepezil or a bladder medicine without the prescribing team's direction.
- Why the bladder medicine was started and whether it still helps
- How long it has been used and whether long-term treatment is intended
- New confusion, sleepiness, memory changes, or reduced daily function
- Difficulty starting urination, incomplete emptying, or other retention concerns
- Other medicines that add to the person's total anticholinergic burden
How strong is the evidence?
The evidence supports caution, not certainty. A 2018 systematic review found mixed outcomes and methodological limitations across only five studies examining these combinations.
That means the research does not establish that every person taking donepezil with a bladder antimuscarinic will develop cognitive or functional harm. 2018 systematic review in Drugs & Aging The practical implication is proportional review. A person with stable cognition and meaningful bladder benefit may have a different decision from someone with new confusion, declining daily function, little bladder benefit, or signs of urinary retention.
Frequently Asked Questions
Does taking donepezil mean a person can never take a bladder antimuscarinic?
No. The evidence does not prove that every combination causes harm. The decision should consider benefit, symptoms, cognition, daily function, duration, and total anticholinergic burden.
Is oxybutynin the only bladder medicine that matters?
No. Oxybutynin has the strongest evidence for adverse cognitive effects, but the Beers Criteria urge caution with all listed bladder antimuscarinics.
Should someone stop one of these medicines immediately?
Do not make a medication change without the prescribing team. Ask a pharmacist or prescriber to review the combination, especially after new confusion, functional decline, or urinary difficulty.
